pharmacological use of peroxisome proliferator-activated receptor (pgc-1 (alpha)) coactivating protein 1 alpha expression inhibitor for the treatment of diabetes mellitus, insulin resistance and metabolic syndrome, its compound and its composition

摘要

"PHARMACOLOGICAL USE OF THE PEROXISOMA PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PGC-1 244) RECEIVER PROTEIN EXPRESSION INHIBITOR, FOR TREATMENT OF DIABETES MELLITUS, RESISTANCE TO INSULIN AND SUMMARY COMPOSIUS SYNDROME, SYNDROME COMPOSITION The present invention relates to the use of an antisense DNA oligonucleotide for PGC-1? Messenger RNA strand useful as a drug for treating diabetes mellitus, insulin resistance and metabolic syndrome. More specifically, the present invention is a compound used as an enteral or parenteral drug, preferably with the property of inhibiting the expression of peroxisome proliferator-activated receptor Coactivator 1 alpha (PGC-1?). ). Leading to lowering blood glucose levels. Therefore, it is a pharmacological compound that promotes, in diabetic and insulin-resistant individuals, improvement of serum glucose levels, increase of plasma insulin concentration and reduction of insulin resistance. The present invention provides a more effective control of glucose levels and acts beneficially on other complications associated with diabetes and obesity, such as liver steatosis, according to tests performed in animal models. Thus, the main advantage of the present invention over similar ones already on the market is the effectiveness with which it controls blood glucose levels and the fact that it acts beneficially on other complications that accompany the disease.